SCHEMBL91644

SCHEMBL91644

FC1(F)CCNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2825 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747234-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS Muna Therapeutics ApS (DK) 2026-05-27 EP claimed
US-20250368635-A1 HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF VORONOI, INC. (KR) 2025-12-04 US claimed
EP-4638518-A1 METHOD FOR PRODUCING AMIDO-METHYLATED VINYL-AROMATIC POLYMERIZATES LANXESS Deutschland GmbH (DE) 2025-10-29 EP claimed
WO-2025215558-A1 COMPOUNDS FOR SPLICING MODULATION FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-10-16 WO claimed
US-12404283-B2 c-MYC mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-09-02 US claimed
WO-2025133191-A1 NOVEL SULFONAMIDES OR SULFONES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS GENECODE (EE) 2025-06-26 WO claimed
EP-4547672-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2025-05-07 EP claimed
US-20250129100-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-24 US claimed
EP-4532014-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 Cerevance, Inc. (US) 2025-04-09 EP claimed
WO-2025017103-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS MUNA THERAPEUTICS APS (DK) 2025-01-23 WO claimed
EP-1786815-A1 SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY Virochem Pharma Inc. (CA) 2007-05-23 EP claimed
EP-1786816-A1 SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY Virochem Pharma Inc. (CA) 2007-05-23 EP claimed
EP-1785418-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-16 EP claimed
EP-1750776-A2 OLIGONUCLEOTIDES COMPRISING A C5-MODIFIED PYRIMIDINE Alnylam Pharmaceuticals Inc. (US) 2007-02-14 EP claimed
WO-2006073458-A2 OLIGONUCLEOTIDES COMPRISING A C5-MODIFIED PYRIMIDINE ALNYLAM PHARMACEUTICALS, INC. (US) 2006-07-13 WO claimed
US-20050288244-A1 Oligonucleotides comprising a C5-modified pyrimidine ALNYLAM PHARMACEUTICALS, INC. (US) 2005-12-29 US claimed
US-20050075360-A1 Spirohydantoin compounds and methods for the modulation of chemokine receptor activity VIRO CHEM PHARMA, INC. (CA) 2005-04-07 US claimed
US-20050070563-A1 Spiro compounds and methods for the modulation of chemokine receptor activity VIRO CHEM PHARMA, INC. (CA) 2005-03-31 US claimed
WO-2005023810-A1 SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY VIROCHEM PHARMA INC. (CA) 2005-03-17 WO claimed
WO-2005023809-A1 SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY VIROCHEM PHARMA INC. (CA) 2005-03-17 WO claimed